![]() Thrombosis occurred in two patients at the 100 mg and 10 mg dose levels. Adverse events were predominantly grades 1-2, most commonly, localised injection-site reactions (44.4%), vomiting (11%), fatigue (16.7%), arthralgia (5.6%) and headache (11%). ALM201 was well-tolerated at all dose levels without CTCAE grade 4 toxicities. Twenty (8 male, 12 female) patients with various solid tumours were treated (18 evaluable for toxicity) over eight planned dose levels (10-300 mg). ALM201 was administered subcutaneously once daily for 5 days every week in unselected patients with solid tumours. We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid tumours. ![]() We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |